The search for dementia prevention strategies has intensified as aging populations face mounting cognitive decline risks. While researchers have long suspected that cardiovascular medications might protect the brain by improving blood flow, definitive evidence has remained elusive until now. A comprehensive genetic analysis in Nature Aging reveals surprising findings about which heart medications truly influence vascular dementia risk. Using Mendelian randomization—a technique that leverages genetic variants as natural experiments—scientists examined whether common drug targets for cholesterol, inflammation, and blood pressure actually prevent vascular dementia. The analysis encompassed multiple drug classes, testing whether genetic mimicry of these medications' effects correlates with reduced dementia risk. Most cardiovascular drug targets showed little protective benefit against vascular dementia, challenging widespread assumptions about their neuroprotective potential. However, the beta-blocker target ADRB1 emerged as a notable exception, demonstrating potential risk reduction. Unexpectedly, ACE inhibition—a cornerstone of heart failure and hypertension treatment—appeared to increase vascular dementia risk in this genetic analysis. These findings represent a significant shift in understanding drug repurposing opportunities for cognitive protection. The Mendelian randomization approach provides more reliable evidence than observational studies, which can be confounded by lifestyle factors and disease severity. For the millions taking cardiovascular medications, this research suggests that not all heart drugs offer equal brain benefits. The ADRB1 finding warrants clinical investigation, while the ACE inhibitor result demands careful consideration given these medications' established cardiovascular benefits. This work exemplifies precision medicine's potential—using genetic evidence to identify which existing drugs might serve dual purposes in protecting both heart and brain health during aging.